Comparison of Weight-Based Dosages of Enteric-Coated Microtablet Enzyme Preparations in Patients with Cystic Fibrosis

Beker, Leila; Fink, Robert; Shamsa, Falah; Chaney, Hollis; Kluft, Janet; Evans, E. L.; Schidlow, Daniel V.

doi:10.1097/00005176-199408000-00009

Cited by 23 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrated that PANCREAZE® was an effective, well tolerated, and safe therapy for maldigestion and malabsorption caused by EPI in CF patients and reaffirmed prior efficacy and safety results [12][13][14][15]. PANCREAZE® improved CFA, CNA and stool consistency and reduced EPI-related symptoms in CF patients with EPI.…”

Section: Discussionsupporting

confidence: 79%

“…PANCREAZE® treatment was adjusted to accommodate a high-fat target diet and to optimize digestion based on clinical signs and symptoms within the CF Foundation recommendations for PERT up to a maximum of 10,000 units lipase/kg/day [12]. The average daily dose of lipase administered during the open-label and double-blind phases (6274 and 6403 units/kg/ day, respectively) was within the range of doses utilized in other studies [4][5][6].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis

Trapnell

Strausbaugh

Woo

et al. 2011

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis

Trapnell

Strausbaugh

Woo

et al. 2011

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first original article describing the extent of malabsorption as well as energy and fat intakes in such a young patient population, being 3 years as the minimal age of participants in other studies [8][9][10]. Malabsorption measurements in the present study suggest that many infants had received suboptimal enzyme doses.…”

Section: Discussionmentioning

confidence: 62%

“…The scientific literature contains very few data on objective measurements of malabsorption in infants with CF or on the efficacy and safety of enzyme preparations in this young age group [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Pancreatic enzyme replacement therapy for young cystic fibrosis patients

Munck

Duhamel

Lamireau

et al. 2009

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Those parents who had a preference favoured CfC over C10. Both enzyme preparations improved malabsorption to a similar degree, although the applied dosages could have been too low in some children reflected in a suboptimal CFA. These data support the use of CfC for young patients with cystic fibrosis improving the daily care of this cohort detected mainly now through neonatal screening programmes.

show abstract

“…The proportion of calories derived from protein, fat, and carbohydrate was similar between the two groups (protein 16 -18%, fat 31-35%, and carbohydrate 49 -58% of total caloric intake). We did not measure stool fat content, but it can be assumed that some portion of the dietary intake was not absorbed in CF patients, since 5-15% of fat is not absorbed despite the use of exogenous pancreatic enzyme supplementation (35,36). None of our patients had obvious symptoms of malabsorption (abdominal pain or malodorous, greasy, or floating stools).…”

Section: Resultsmentioning

confidence: 97%

Protein Metabolism in Clinically Stable Adult Cystic Fibrosis Patients With Abnormal Glucose Tolerance

et al. 2001

View full text Add to dashboard Cite

In contrast, striking abnormalities were seen in CF patients when insulin was infused, since they did not experience normal suppression of the appearance rates of leucine, phenylalanine, or tyrosine (indexes of protein breakdown). At an insulin concentration of 45 ؎ 2 U/ml, normal control subjects suppressed the leucine appearance rate by 19 ؎ 5% (P < 0.01), ketoisocaproate appearance rate by 10 ؎ 3% (P ‫؍‬ 0.03), tyrosine appearance rate by 11 ؎ 2% (P ‫؍‬ 0.03), and phenylalanine appearance rate by 6 ؎ 3% (P ‫؍‬ 0.07). Phenylalanine conversion to tyrosine decreased by 22 ؎ 7% (P ‫؍‬ 0.03). At a similar insulin concentration of 44 ؎ 3 U/ml, normal suppression of amino acid appearance did not occur in CF. The leucine appearance rate decreased by 4 ؎ 2% (P ‫؍‬ 0.65), ketoisocaproate appearance rate by 1 ؎ 2% (P ‫؍‬ 0.94), tyrosine appearance rate by 0 ؎ 6% (P ‫؍‬ 0.56), phenylalanine appearance rate by 5 ؎ 6% (P ‫؍‬ 0.34), and phenylalanine conversion to tyrosine by 5 ؎ 6% (P ‫؍‬ 0.95). Poor suppression of the amino acid appearance rate in CF was not related to previously documented glucose tolerance status (IGT or CF-related diabetes without fasting hyperglycemia), fasting insulin levels, the acute insulin response, insulin sensitivity, cytokine or counterregulatory hormone levels, resting energy expenditure, caloric intake, pulmonary function, or clinical status. Protein synthesis was not significantly affected by insulin infusion in either normal control subjects or CF patients. In conclusion, clinically stable adult CF patients have normal indexes of protein breakdown and synthesis in the fasting state. In contrast, elevation of plasma insulin to physiological postprandial levels fails to normally suppress indexes of protein breakdown. It is therefore likely that inability to spare protein during the postprandial state is the cause of protein catabolism in these patients. Diabetes

show abstract

Comparison of Weight-Based Dosages of Enteric-Coated Microtablet Enzyme Preparations in Patients with Cystic Fibrosis

Cited by 23 publications

References 0 publications

Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis

Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis

Pancreatic enzyme replacement therapy for young cystic fibrosis patients

Protein Metabolism in Clinically Stable Adult Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Contact Info

Product

Resources

About